-+ 0.00%
-+ 0.00%
-+ 0.00%

Alpha-9 Oncology doses first patient in Phase 1 trial of GRPR-targeted radiotherapeutics

PUBT·09/10/2026 13:30:08
Listen to the news
Alpha-9 Oncology doses first patient in Phase 1 trial of GRPR-targeted radiotherapeutics
  • Lumira Capital portfolio company Alpha-9 Oncology dosed the first patient in a Phase 1 GRPR-targeted radiotherapeutics trial.
  • Study evaluates 225Ac-A9-0642, an actinium-based GRPR compound, alongside 177Lu-A9-0631, a lutetium-based program, in solid tumors.
  • Trial targets GRPR-positive advanced or metastatic disease, including breast cancer; endpoints include safety, tolerability, dosimetry, dose for expansion.
  • Alpha-9 will use its 68Ga-A9-6217 imaging agent for patient selection; initial data expected in late 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lumira Capital Investment Management Inc published the original content used to generate this news brief on September 10, 2026, and is solely responsible for the information contained therein.